Seeking Alpha

Endo Health Solutions (ENDP) trades higher after hours as the FDA says it won't approve generic...

Endo Health Solutions (ENDP) trades higher after hours as the FDA says it won't approve generic copies of the old version of OxyContin. The first patent on the old version expired today, and drug makers had been lining up to make copies. But the newer, reformulated OxyContin was found to be tougher to crush, break or dissolve, the FDA said, and "the benefits of the old formulation no longer outweigh its risks." Shares +5.6% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector